Blackstone Inc
DNTH icon

Blackstone Inc’s Dianthus Therapeutics DNTH Stock Holding History

Blackstone Inc’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$701K Sell
7,193
-27,852
-79% -$2.43M ﹤0.01% 296
2026
Q1 		$2.94M Buy
+35,045
New +$2.03M 0.01% 170
2018
Q3 		– Sell
-1,094
Closed -$236K – 59
2018
Q2 		$236K Buy
+1,094
New +$247K ﹤0.01% 80

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Blackstone Inc's DNTH Position: Q2 2026 in Review

Blackstone Inc reduced its Dianthus Therapeutics (DNTH) stake by 79% in Q2 2026, selling an estimated $2.43M and leaving 7,193 shares worth $701K. The position accounts for ﹤0.01% of the portfolio, ranked #296.

Blackstone Inc first reported a position in DNTH in Q2 2018 and has held it in 3 quarters since. The position peaked at $2.94M in Q1 2026. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Blackstone Inc held 7,193 shares of Dianthus Therapeutics worth $701K as of Q2 2026.
  • Blackstone Inc sold 27,852 Dianthus Therapeutics shares in Q2 2026, an estimated $2.43M.
  • Dianthus Therapeutics made up ﹤0.01% of Blackstone Inc's portfolio in Q2 2026, its #296 holding.
  • Blackstone Inc first reported a position in Dianthus Therapeutics in Q2 2018 and has held it in 3 quarters since.
  • Blackstone Inc's Dianthus Therapeutics position peaked at $2.94M in Q1 2026.
  • 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Blackstone Inc's 13F filing for Q2 2026, filed 14 Aug 2026.